Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
- 106 Downloads
The purposes of this study are to study the impact of deep brain involvement on overall survival (OS) and progression-free survival (PFS) in intracranial primary CNS lymphoma (PCNSL), and to explore possible mechanisms for this impact using advanced MRI techniques.
Seventy-nine patients with histologically verified PCNSL were identified from a prospective clinical database of patients treated at Oslo University Hospital between 2003 and 2014. Patients were treated per standard chemotherapeutic regimens (N = 57) or no chemotherapy (N = 22). Anatomical MRIs were available in all patients to assess tumor load and location based on contrast agent enhancement visible on T1-weighted images. Diffusion MRIs were available in 33 (42%) patients and perfusion MRI in 13 (16%) patients that received active treatment.
Across all patients, OS and PFS were 16.4 and 9.8 months, respectively. In multivariate analysis, MRI-based deep brain involvement (80%) was the only negative significant factor of OS (OR = 14.2; P < 0.005). While a reduced Karnofsky performance status was associated with deep brain involvement (P < 0.05), neither chemotherapy regimen, neurologic status, nor patient age were independent significant factors for OS or PFS in this setting. Compared to other tumors and healthy tissue levels, MRI perfusion showed more pathologic hemodynamic flow signatures in tumors with deep brain involvement.
In intracranial PCNSL, the only significant prognostic factor for OS and PFS in multivariate analysis was age and deep brain involvement. While contingent on a small study sample, we hypothesize this may in part be explained by regional differences in vascular supply and delivery from a dysfunctional perfusion signature.
KeywordsLymphoma Oncology Prognostic factors MRI Surgery
Compliance with ethical standards
No funding was received for this study.
Conflict of interest
KEE has intellectual property rights at NordicNeuroLab AS, Bergen, Norway.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
For this type of retrospective study formal consent is not required.
- 3.Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J (2004) Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59(2):501–508CrossRefPubMedGoogle Scholar
- 4.Jahr G, Da Broi M, Holthe Jr H, Beiske K, Meling TR (2018) Evaluation of MSKCC and IELSG prognostic scoring systems to predict overall survival in intracranial primary CNS lymphoma. Brain Behav in pressGoogle Scholar
- 6.Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G (2013) Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 98(5):765–770CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O et al (2010) Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 21(4):842–850CrossRefPubMedGoogle Scholar
- 13.Lister A, Abrey LE, Sandlund JT (2002) Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2002(1):283–296Google Scholar
- 16.Pulczynski EJ, Kuittinrn O, Erlanson M, Hagberg H, Nordstrøm M, Østenstad B et al (2015) Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic lymphoma group. Haematologica 100:534–540CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Neska-Matuszewska M, Bladowska J, Sasiadek M, Zimny A (2018) Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-searching for a practical approach. PLoS One 13(1):e0191341CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis L, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, International Primary CNS Lymphoma Collaborative Group (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034–5043CrossRefPubMedGoogle Scholar
- 23.Kim YS, Choi SH, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park SH, Won JK, Kim TM, Park CK, Kim IH (2018) Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. Sci Rep 8(1):456CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Shin W, Horowitz S, Ragin A, Chen Y, Walker M, Carroll TJ (2007) Quantitative cerebral perfusion using dynamic susceptibility contrast MRI: evaluation of reproducibility and age- and gender-dependence with fully automatic image postprocessing algorithm. Magn Reson Med 58(6):1232–1241CrossRefPubMedGoogle Scholar
- 29.Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14(2):556–564CrossRefPubMedGoogle Scholar
- 33.Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M, European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16(7):e322–e332CrossRefPubMedGoogle Scholar
- 37.Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31(31):3971–3979CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Houillier C, Ghesquieres H, Chabrot C, Soussain C, Ahle G, Choquet S et al (2017) Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neuro-Oncol 133(2):315–320CrossRefGoogle Scholar